Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood ...

University of Wisconsin–Madison–led researchers report lower yet statistically non-significant recurrence of Clostridioides ...

A recently published study revealed significant sex-based disparities in emergency department empiric antibiotic treatment ...

Long-acting lipoglycopeptides are as effective as standard-of-care antibiotics in treating serious bacterial infections in ...

Normally, skin cells take about a month to form and rise to the surface. In people with psoriasis, this process happens in ...

Inappropriate polypharmacy—the excessive or unnecessary use of multiple medications—is a major driver of emergency hospital ...

The FDA has approved Gamifant for the treatment of adult and pediatric patients with HLH/MAS in known or suspected Still disease.

Middle ear infection in children is much more common than in adults, in part because of how this part of the ear is designed.

Dental care delays are common, but they come with risks. Learn what causes them and how we can change the pattern.

The following column was originally published June 6, 2020. Thanks to breakthroughs in medicine and nutrition in recent years, we are living longer than ever before. But this increase in life ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult ...

Vaccination programs have saved lives – and saved the Canadian economy and health care system significant resources as well ...